214 related articles for article (PubMed ID: 28645940)
1. T-cell Receptors for Clinical Therapy:
Kunert A; Obenaus M; Lamers CHJ; Blankenstein T; Debets R
Clin Cancer Res; 2017 Oct; 23(20):6012-6020. PubMed ID: 28645940
[TBL] [Abstract][Full Text] [Related]
2. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
Stone JD; Harris DT; Kranz DM
Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
4. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
5. High-throughput discovery of cancer-targeting TCRs.
Bunse L; Green EW; Platten M
Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.
Hammerl D; Rieder D; Martens JWM; Trajanoski Z; Debets R
Trends Immunol; 2018 Nov; 39(11):921-936. PubMed ID: 30309702
[TBL] [Abstract][Full Text] [Related]
7. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
9. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
10. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
11. TCR validation toward gene therapy for cancer.
Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
[TBL] [Abstract][Full Text] [Related]
12. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
Front Immunol; 2021; 12():658753. PubMed ID: 33859650
[TBL] [Abstract][Full Text] [Related]
13. Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.
Spear TT; Wang Y; Smith TW; Simms PE; Garrett-Mayer E; Hellman LM; Baker BM; Nishimura MI
Mol Ther; 2018 Apr; 26(4):996-1007. PubMed ID: 29503203
[TBL] [Abstract][Full Text] [Related]
14. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
15. TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets R; Donnadieu E; Chouaib S; Coukos G
Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
[TBL] [Abstract][Full Text] [Related]
16. MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.
Kunert A; van Brakel M; van Steenbergen-Langeveld S; da Silva M; Coulie PG; Lamers C; Sleijfer S; Debets R
J Immunol; 2016 Sep; 197(6):2541-52. PubMed ID: 27489285
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
18. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
[TBL] [Abstract][Full Text] [Related]
19. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
20. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
